Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Michael W Donnino, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. mdonnino@bidmc.harvard.edu.
  • ,
  • Lars Wiuff Andersen
  • Katherine M Berg, Department of Medicine, Division of Pulmonary and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Maureen Chase, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Robert Sherwin, Department of Emergency Medicine, Wayne State University School of Medicine, Detroit, MI, USA.
  • ,
  • Howard Smithline, Department of Emergency Medicine, Baystate Medical Center, Springfield, MA, USA.
  • ,
  • Erin Carney, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Medicine, Division of Pulmonary and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Long Ngo, Department of Medicine, Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Parth V Patel, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Medicine, Division of Pulmonary and Critical Care, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Xiaowen Liu, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Donald Cutlip, Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Peter Zimetbaum, Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Michael N Cocchi, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • ,
  • Collaborating Authors from the Beth Israel Deaconess Medical Center’s Center for Resuscitation Science Research Group

BACKGROUND: The purpose of this study was to determine whether the provision of corticosteroids improves time to shock reversal and outcomes in patients with post-cardiac arrest shock.

METHODS: We conducted a randomized, double-blind trial of post-cardiac arrest patients in shock, defined as vasopressor support for a minimum of 1 hour. Patients were randomized to intravenous hydrocortisone 100 mg or placebo every 8 hours for 7 days or until shock reversal. The primary endpoint was time to shock reversal.

RESULTS: Fifty patients were included with 25 in each group. There was no difference in time to shock reversal between groups (hazard ratio: 0.83 [95% CI: 0.40-1.75], p = 0.63). We found no difference in secondary outcomes including shock reversal (52% vs. 60%, p = 0.57), good neurological outcome (24% vs. 32%, p = 0.53) or survival to discharge (28% vs. 36%, p = 0.54) between the hydrocortisone and placebo groups. Of the patients with a baseline cortisol < 15 ug/dL, 100% (6/6) in the hydrocortisone group achieved shock reversal compared to 33% (1/3) in the placebo group (p = 0.08). All patients in the placebo group died (100%; 3/3) whereas 50% (3/6) died in the hydrocortisone group (p = 0.43).

CONCLUSIONS: In a population of cardiac arrest patients with vasopressor-dependent shock, treatment with hydrocortisone did not improve time to shock reversal, rate of shock reversal, or clinical outcomes when compared to placebo.

CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov: NCT00676585, registration date: May 9, 2008.

OriginalsprogEngelsk
TidsskriftCritical Care
Vol/bind20
Sider (fra-til)82
ISSN1466-609X
DOI
StatusUdgivet - 3 apr. 2016

Se relationer på Aarhus Universitet Citationsformater

ID: 108417078